TBPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Theravance Biopharma Inc (TBPH) is not a strong buy at the moment for a beginner investor with a long-term horizon. While the company has shown some positive revenue growth, the recent failure of its Phase 3 CYPRESS study, ongoing legal investigations, and significant financial losses make it a risky investment. Additionally, there are no strong trading signals or positive catalysts to justify immediate action.
The technical indicators are mixed. The MACD is slightly positive, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the RSI is neutral at 40.747, and the stock is trading near its support level of 16.301, suggesting limited upside potential in the short term.
The company has locked exclusivity through April 2039 for its single-asset story, which removes some uncertainty. Additionally, Yupelri continues to grow and generate milestones, and Trelegy payments remain significant.
The failure of the Phase 3 CYPRESS study and the discontinuation of the ampreloxetine program have significantly impacted the company's prospects. The ongoing investigation for potential securities fraud and unlawful business practices adds further risk. Additionally, the company has experienced a sharp decline in net income and EPS.
In Q4 2025, revenue increased by 144.70% YoY to $45.89M, but net income dropped by -493.02% YoY to -$61.02M. EPS also fell by -470.97% YoY to 1.15. Despite a 100% gross margin, the financial performance indicates significant challenges.
Analyst sentiment is mixed to negative. Recent upgrades raised price targets slightly (e.g., B. Riley to $17 from $14), but the stock has seen multiple downgrades following the CYPRESS study failure. Analysts highlight limited visibility into upside drivers and significant cost-cutting measures.
